| 22-01-07 | Delisting of AS "Olainfarm” shares from the Baltic Main list | AQ |
| 22-01-06 | Notification about results of final buy-back of shares | AQ |
| 21-12-30 | Notification about final share buy-back | AQ |
| 21-12-28 | Correction: Regarding results of a share buy-back offer | AQ |
| 21-12-28 | On substantial participation (4) - specified | AQ |
| 1 day | +7.19% |
| Manager | Title | Age | Since |
|---|---|---|---|
Juris Hmelnickis
CEO | Chief Executive Officer | 46 | 2025-12-31 |
Janis Leimanis
DFI | Director of Finance/CFO | 56 | - |
| Chief Tech/Sci/R&D Officer | - | 2009-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 2021-06-18 | |
Janis Buks
CHM | Chairman | - | 2022-08-31 |
Roberts Tavjevs
BRD | Director/Board Member | - | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/4/21 | Sell | Chief Financial Officer | 97,424 | 0.6917% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +7.19% | +2.67% | - | - | 148M | |
| +2.70% | +2.73% | +40.91% | +110.31% | 1,032B | |
| +1.44% | -2.38% | +36.83% | +63.95% | 614B | |
| +1.75% | +3.73% | +16.55% | +83.05% | 471B | |
| +0.60% | -1.73% | +62.98% | +37.46% | 350B | |
| +2.92% | +3.12% | +24.78% | +45.10% | 337B | |
| +2.42% | +0.05% | +14.13% | +35.80% | 268B | |
| +1.86% | -0.81% | -4.69% | +12.20% | 246B | |
| +2.60% | -2.00% | +39.77% | +54.44% | 218B | |
| +1.82% | -1.48% | +25.75% | +96.48% | 179B | |
| Average | +2.03% | -1.16% | +28.56% | +59.87% | 412.76B | |
| Weighted average by Cap. | +0.81% | -0.47% | +32.01% | +70.59% |
Employees
2,191
Sector
Pharmaceuticals
